title: Different Platelet Count Thresholds to Guide Use of Prophylactic Platelet Transfusions for Patients With Hematological Disorders After Myelosuppressive Chemotherapy or Stem Cell Transplantation.
abstract: OBJECTIVE
  What is the optimal platelet count threshold for prophylactic platelet transfusions to minimize bleeding, platelet use, and adverse clinical outcomes in thrombocytopenic patients with hematological malignant neoplasms?
  
  
  CONCLUSIONS
  Maintaining a higher platelet count threshold (≤20 × 109/L or ≤30 × 109/L) was not associated with less bleeding than the current standard (≤10 × 109/L), but required more platelet transfusions (low-quality evidence).
authors.affiliation: NHS Blood and Transplant, National Institute for Health Research (NIHR) Oxford Biomedical Research Centre; Radcliffe Department of Medicine, University of Oxford, Oxford, England.
authors.forename: Lise J
authors.initials: LJ
authors.lastname: Estcourt
authors.affiliation: NHS Blood and Transplant, National Institute for Health Research (NIHR) Oxford Biomedical Research Centre; Radcliffe Department of Medicine, University of Oxford, Oxford, England.
authors.forename: Simon J
authors.initials: SJ
authors.lastname: Stanworth
authors.affiliation: NHS Blood and Transplant, National Institute for Health Research (NIHR) Oxford Biomedical Research Centre; Radcliffe Department of Medicine, University of Oxford, Oxford, England.
authors.forename: Michael F
authors.initials: MF
authors.lastname: Murphy
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects*; D006402:Hematologic Diseases / Q000628:therapy*; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006470:Hemorrhage / Q000517:prevention & control*; D006801:Humans; D007938:Leukemia / Q000188:drug therapy*; D010976:Platelet Count; D017713:Platelet Transfusion / Q000379:methods*; D013921:Thrombocytopenia / Q000097:blood / Q000209:etiology / Q000628:therapy*
chemical_list: D000970:Antineoplastic Agents